Skip to main content
. 2016 Sep 29;10:676. doi: 10.3332/ecancer.2016.676

Table 1. Baseline characteristics and clinical outcomes.

Demographic/clinical characteristic n = 176
Median age (range) 55 (13–76)
Males (%) 140 (79%)
IMDC criteria (n, %)
Favourable 36 (20%)
Intermediate 109 (62%)
Poor 31 (18%)
Best Response to HDIL-2
CR 16 (9%)
PR 11 (6%)
Stable disease (SD) 52 (30%)
Progressive disease (PD)/Not evaluable (NE) 97 (58%)
PFS (median) 5.6
OS (median) 19.9